This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker's (SYK) New Tech Aims to Improve Surgeon's Efficiency
by Zacks Equity Research
Stryker's (SYK) Blueprint Mixed Reality Guidance system aims to benefit shoulder arthroplasty surgeons by improving efficiency and minimizing errors.
Casey's General Stores and Westlake have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Casey's General Stores and Westlake are part of the Zacks Bull and Bear of the Day article.
Generative AI Reshapes Healthcare: 3 Stocks in Limelight
by Zacks Equity Research
Stocks like Medtronic (MDT), Stryker (SYK) and NVIDIA (NVDA) are likely to benefit from the rising prospects of Generative AI in healthcare.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Will Stryker (SYK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
HAE vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights Berkshire Hathaway, Mastercard, ServiceNow, Applied Materials and Stryker
by Zacks Equity Research
Berkshire Hathaway, Mastercard, ServiceNow, Applied Materials and Stryker are included in this Analyst Blog.
Top Stock Reports for Berkshire Hathaway, Mastercard & ServiceNow
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Mastercard Incorporated (MA) and ServiceNow, Inc. (NOW).
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
HAE vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
HAE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?
Here's What Key Metrics Tell Us About Stryker (SYK) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.
Stay Ahead of the Game With Stryker (SYK) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Medical Product Stocks' Q3 Earnings Due on Nov 1: SYK & More
by Indrajit Bandyopadhyay
Third-quarter results of Medical Product companies are likely to reflect a year-over-year decline. Let's see how SYK, COR, BAX, FMS and XRAY fare this time around.
Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.
BAX vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAX vs. SYK: Which Stock Is the Better Value Option?
Stryker (SYK) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Stryker (SYK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Cisco, Stryker, Enbridge, Suncor and Splunk
by Zacks Equity Research
Cisco, Stryker, Enbridge, Suncor and Splunk are included in this Analyst Blog.
Top Research Reports for Cisco Systems, Stryker & Enbridge
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Cisco Systems, Inc. (CSCO), Stryker Corporation (SYK) and Enbridge Inc. (ENB).
Will Stryker (SYK) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
5 Medical Product Stocks to Buy Amid Industry Recovery
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.
Reasons to Add Stryker (SYK) Stock to Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.
HAE vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. SYK: Which Stock Is the Better Value Option?